Advertisement
Amneal Pharmaceuticals, Inc. (AMRX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 8.32 |
| Open | 8.38 |
| Bid | 8.36 x 300 |
| Ask | 8.42 x 500 |
| Day's Range | 8.25 - 8.43 |
| 52 Week Range | 4.16 - 9.48 |
| Volume | |
| Avg. Volume | 1,106,229 |
| Market Cap | 3.876B |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings Date | Nov 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
Business WireAmneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
GuruFocus.comAmneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Amneal Pharmaceuticals Inc (AMRX) reports robust Q3 performance with significant strides in new markets and innovative product launches.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.